The Raj Laboratory has developed significant expertise in:
- Deciphering mechanisms of resistance to therapy: understanding why and how drugs or radiation fail is critical to developing novel approaches to targeting therapy resistance
- Evaluating protein-protein interactions
- We have experience using co-immunoprecipitations, proximity ligation assays, and in vivo complementation assays for individual interactions
- We have experience with IP-MS and RIME for global interactions
- Targeting protein-protein interactions
- In collaboration with Jung-Mo Ahn, Ph.D., UT Dallas, we have created a new class of drugs known as peptidomimetics
- Some of these drugs have activity in therapy-resistant prostate and breast cancers
- These drugs are being translated to clinical trials
- Evaluating ex vivo cultures of prostate cancer
- The Raj Laboratory has the largest experience in the world in growing cancer tissues from primary and metastatic sites in explant cultures
- We have developed patient-derived explants (PDEx), patient-derived xenograft explants (PDXEx), and xenograft-derived explants (XDEx)
- Animal and cellular models of prostate and breast cancer
- We have developed multiple models, including several unique to the laboratory